ContraFect to Present CF-301 Phase 1 Trial Data at the 26th ECCMID Conference

YONKERS, NY–(Marketwired – March 29, 2016) – ContraFect Corporation (NASDAQ:CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it will present new clinical data from a Phase 1 clinical trial of CF-301 at the 26th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) to be held on April 9-12, 2016 in Amsterdam.

This entry was posted in Recent Development News: Q1 - 2016, Recent Developments. Bookmark the permalink.
Read Full Article »